Quotes 5-day view Delayed Nasdaq
05/16/2022
05/17/2022
05/18/2022
05/19/2022
05/20/2022
Date
129.18(c)
138.58(c)
131.09(c)
131.67(c)
137.32 Last
228 845
191 194
286 151
361 490
259 493 Volume
-2.78% +7.28% -5.40% +0.44% +4.29% Change
Estimated financial data (e) (USD)
Sales 2022
1 429 M - -
Net income 2022
-1 407 M - -
Net cash position 2022
2 668 M - -
P/E ratio 2022
-8,87x
Yield 2022
-
Sales 2023
2 108 M - -
Net income 2023
-1 051 M - -
Net cash position 2023
1 449 M - -
P/E ratio 2023
-9,80x
Yield 2023
-
Capitalization
13 585 M 13 585 M -
EV / Sales 2022
7,64x
EV / Sales 2023
5,76x
Nbr of Employees
8 300
Free-Float
99,0%
Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217,...
All news about BEIGENE, LTD.
05/17 BeiGene to Open Regional Office in Switzerland MT
05/17 BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi.. BU
05/17 BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland CI
05/12 BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato.. BU
05/11 Asian ADRs Move Higher in Wednesday Trading MT
05/10 Asian ADRs Climb Higher in Tuesday Trading MT
05/09 Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra.. MT
05/09 INSIDER SELL : BeiGeneMT
05/09 BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results
.. AQ
05/05 BeiGene Swings to Q1 Net Loss as Revenue Declines MT
05/05 Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M MT
05/05 BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..AQ
05/05 BeiGene Reports First Quarter 2022 Financial Results BU
05/05 BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
05/04 BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute.. MT
News in other languages on BEIGENE, LTD.
Analyst Recommendations on BEIGENE, LTD.
Exclusive - Chinese regulators ask some U.S.-listed firms to prepare for audit disclosures - sources
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BEIGENE, LTD.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
17
Last Close Price
131,67 $
Average target price
312,07 $
Spread / Average Target
137%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
